Nuclear factor-κB inhibition and non-alcoholic steatohepatitis: Inflammation as a target for therapy

Gut

Volumn 57, Issue 5, 2008, Pages 570-572

  Marra, Fabio ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

1 [5 HYDROXY 2 (2 THIENYL) 4 QUINAZOLINYLAMINO] 3 METHYL 2,5 PYRROLEDIONE; ADIPOCYTOKINE; BORTEZOMIB; CHEMOKINE; FATTY ACID; GLUCOCORTICOID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; SALAZOSULFAPYRIDINE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; THALIDOMIDE; BIOLOGICAL MARKER;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL FEATURE; DISEASE COURSE; DRUG EFFECT; DYSLIPIDEMIA; HUMAN; HYPERTENSION; INFLAMMATION; INHIBITION KINETICS; INSULIN RESISTANCE; LIVER CELL DAMAGE; LIVER CIRRHOSIS; NONALCOHOLIC FATTY LIVER; NONHUMAN; NOTE; OBESITY; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; ANIMAL; DRUG ANTAGONISM; FATTY LIVER; HEPATITIS; METABOLISM; MOUSE;

ANIMALS; BIOLOGICAL MARKERS; FATTY LIVER; HEPATITIS; HUMANS; MICE; NF-KAPPA B;

EID: 42549108683     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2007.141986     Document Type: Note

References (30)

1. Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003;37:917-23.
2. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002;346:1221-31.
3. Ekstedt M, Franzen LE, Mathiesen UL, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006;44:865-73.
4. Bugianesi E, Leone N, Vanni E, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002;123:134-40.
5. Loria P, Lonardo A, Bellentani S, et al. Non-alcoholic fatty liver disease (NAFLD) and cardiovascular disease: an open question. Nutr Metab Cardiovasc Dis 2007;17:684-98.
6. Bellentani S, Dalle Grave R, Suppini A, Marchesini G, Fatty Liver Italian Network. Rehavior therapy for nonalcoholic fatty liver disease: the need for a multidisciplinary approach. Hepatology 2008;47:746-54.
7. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006;43:S99-112.
8. Kaplowitz N, Than TA, Shinohara M, et al. Endoplasmic reticulum stress and liver injury. Semin Liver Dis 2007;27:367-77.
9. Karin M, Yamamoto Y, Wang QM. The IKK NF-kappa B System: a treasure trove for drug development. Nat Rev Drug Discov 2004;3:17-26.
10. Elsharkawy AM, Mann DA. Nuclear factor-kappaB and the hepatic inflammation-fibrosis-cancer axis. Hepatology 2007;46:590-7.
11. Dela Pena A, Leclercq I, Field J, et al. NF-kappaB activation, rather than TNF, mediates hepatic inflammation in a murine dietary model of steatohepatitis. Gastroenterology 2005;129:1663-74.
12. Ribeiro PS, Cortez-Pinto H, Sola S, et al. Hepatocyte apoptosis, expression of death receptors, and activation of NF-kappaB in the liver of nonalcoholic and alcoholic steatohepatitis patients. Am J Gastroenterol 2004;99:1708-17.
13. Cai D, Yuan M, Frantz DF, et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med 2005;11:183-90.
14. Arkan MC, Hevener AL, Greten FR, et al. IKK-beta links inflammation to obesity-induced insulin resistance. Nat Med 2005;11:191-8.
15. Beraza N, Malato Y, Vander Borght S, et al. Pharmacological IKK2 inhibition blocks liver steatosis and initiation of non-alcoholic- steatohepatitis. Gut 2008;57:655-63
16. Edmison J, McCullough AJ. Pathogenesis of nonalcoholic steatohepatitis: human data. Clin Liver Dis 2007;11:75-104, ix.
17. Shoelson SE, Herrero L, Naaz A. Obesity, inflammation, and insulin resistance. Gastroenterology 2007;132:2169-80.
18. Tilg H, Hotamisligil GS. Nonalcoholic fatty liver disease: cytokine-adipokine interplay and regulation of insulin resistance. Gastroenterology 2006;131:934-45.
19. Oakley F, Meso M, Iredale JP, et al. Inhibition of inhibitor of kappaB kinases stimulates hepatic stellate cell apoptosis and accelerated recovery from rat liver fibrosis. Gastroenterology 2005;128:108-20.
20. Ota T, Takamura T, Kurita S, et al. Insulin resistance accelerates a dietary rat model of nonalcoholic steatohepatitis. Gastroenterology 2007;132:282-93.
21. Olivier S, Robe P, Bours V. Can NF-kappaB be a target for novel and efficient anti-cancer agents? Biochem Pharmacol 2006;72:1054- 68.
22. Schwabe RF, Brenner DA. Nuclear factor-kappaB in the liver: friend or foe? Gastroenterology 2007;132:2601-4.
23. Luedde T, Beraza N, Kotsikoris V, et al. Deletion of NEMO/IKKgamma in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma. Cancer Cell 2007;11:119-32.
24. Lee DF, Kuo HP, Chen CT, et al. IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway. Cell 2007;130:440-55.
25. Medina J, Arroyo AG, Sanchez-Madrid F, et al. Angiogenesis in chronic inflammatory liver disease. Hepatology 2004;39:1185-95.
26. Cao Y. Angiogenesis modulates adipogenesis and obesity. J Clin Invest 2007;117:2362-8.
27. Hirosumi J, Tuncman G, Chang L, et al. A central role for JNK in obesity and insulin resistance. Nature 2002;420:333-6.
28. Kanda H, Tateya S, Tamori Y, et al. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest 2006;116:1494-505.
29. Schwabe RF, Seki E, Brenner DA. Toll-like receptor signaling in the liver. Gastroenterology 2006;130:1886-900.
30. Seki E, De Minicis S, Osterreicher CH, et al. TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat Med 2007;13:1324-32.